Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.
Also called NCT01649466
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 162 participants
- Sponsor
- Registry
-
NCT01649466 -
2012-001143-46
-
- Other papers using this trial's data
- Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01649466. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.
- Acronym
- BENEFIT
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LAF237
- Intervention (Drug)
- Protaphane
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01649466- Content hash
f8fa0933af1043242dbad871586fcfb8da328c8c8ae8e849d724ecc8ef9753eb